Sir -Leukotriene B4 (LTB4) formed through 5-lipoxygenation of arachidonic acid shows potent biological actions aligned to the high incidence of immunological deficiencies and inflammatory symptoms associated with human head and neck cancer (Papenhausen et al., 1979; Bray, 1983) . Although homogenates of human squamous cell carcinomas (HSCC) contain 5, 12 and 15 hydroxyeicosatetraenoic acids the presence of LTS has yet to be established (El-Attar et al., 1985) .
Tumour tissue was obtained from the cheek pouch of nine Syrian hamsters after 12 weeks of three applications of dimethylbenzanthracene (DMBA 0.5% in mineral oil) per week as previously described (Eveson, 1981) . Animals painted with vehicle alone served as controls. Human studies were carried out in cancerous and unaffected control tissue from eight patients undergoing resection for squamous cell carcinoma of the head and neck. Clinical indices were routinely measured and previous treatments recorded.
Each tissue was extracted in ice-cold ethanol (80%) in the presence of 3H-LTB4 (2 nCi, 32 Ci mmol-1) for recovery estimation. Samples were then purified by reverse-phase high performance liquid chromatography (Mathews et al., 1981) and LTB4 was measured by specific radioimmunoassay using a double antibody technique (Hayes et al., 1983) .
Our results (Table I) show the presence of LTB4-ir in animal and HSCC in amounts similar to that observed for other arachidonic acid metabolites, of which prostaglandin E2 (PGE2) has received much attention (Porteder et al., 1984) . A likely source of LTB4 could be inflammatory or malignant cells.
The effects of 5-lipoxygenase products on tumour biology are not well understood but a role for LTB4 as a mediator of inflammation (Ford-Hutchinson et al., 1980) , and immunoregulation (Rola-Pleszczynski & Sirios, 1983) has been proposed. In the inflammatory response, LTB4 stimulates increased vascular permeability and oedema responses particularly in the presence of vasodilator substances such as PGE2 (Wedmore & Williams, 1980) . LTB4 significantly inhibits human mitogen-induced lymphocyte proliferation in vitro probably provided through PGE2 release leading to (Hansen, 1987 
